Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2013
Filed with the SEC on Aug 9, 2013 and accepted by EDGAR at Aug 9, 2013, 17:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-04-01 to 2013-06-30 | $7.1m | us-gaap:SalesRevenueNet |
| Revenue | 6 months2013-01-01 to 2013-06-30 | $17.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2013-04-01 to 2013-06-30 | $1.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2013-01-01 to 2013-06-30 | $2.3m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2013-04-01 to 2013-06-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2013-01-01 to 2013-06-30 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2013-04-01 to 2013-06-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-01-01 to 2013-06-30 | $185.5k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-04-01 to 2013-06-30 | $20.7k | us-gaap:InterestExpense |
| Interest expense | 6 months2013-01-01 to 2013-06-30 | $38.4k | us-gaap:InterestExpense |
| Income tax | 3 months2013-04-01 to 2013-06-30 | −$463.4k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2013-01-01 to 2013-06-30 | $96.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-04-01 to 2013-06-30 | −$639.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-01-01 to 2013-06-30 | $215.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-04-01 to 2013-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2013-01-01 to 2013-06-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-04-01 to 2013-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2013-01-01 to 2013-06-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-04-01 to 2013-06-30 | 18,405,522 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2013-01-01 to 2013-06-30 | 18,756,691 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2013-01-01 to 2013-06-30 | $1.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2013-01-01 to 2013-06-30 | $69.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2013-01-01 to 2013-06-30 | $3.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2013-06-30 | $49.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-06-30 | $82.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-06-30 | $95.5m | us-gaap:Assets |
| Current liabilities | At period end2013-06-30 | $6.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-06-30 | $12.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-06-30 | $83.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001087294-13-000009. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.